References
- Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-47
- Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296-305
- Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80
- Gandjour A, Lauterbach KW. An evidence-based disease-management program for patients with diabetic nephropathy. J Nephrol 2003;16(4):500-10
- Icks A, Haastert B, Gandjour A, et al. Costs of dialysis–a regional population-based analysis. Nephrol Dial Transplant 2010;25(5):1647-52
- Palmer AJ, Valentine WJ, Chen R, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant 2008;23(4):1216-23
- Adarkwah CC, Gandjour A. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany. Int J Technol Assess Health Care 2010;26(1):62-70
- Erickson KF, Japa S, Owens DK, et al. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol 2013;61(12):1250-8
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter Suppl 2013;3:1-150
- Bundesministerium für Gesundheit. Gesetzliche Krankenversicherung: Kennzahlen und Faustformeln. Bonn, Berlin: 2012
- Anonymous. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis 2002;39(2 Suppl 2):S1-S246
- Gold MR, Siegel JE, Weinstein MC, Russell LB. Cost-effectiveness in health and medicine. Oxford University Press; New York: 1996
- Brenner BM, Cooper ME, de Zeeuw D, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
- Mafham M, Emberson J, Landray MJ, et al. Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis. PLoS One 2011;6(10):e25920
- Icks A, Haastert B, Genz J, et al. Time-dependent impact of diabetes on the mortality of patients on renal replacement therapy: a population-based study in Germany (2002-2009). Diabetes Res Clin Pract 2011;92(3):380-5
- Scheuringer M, Sahakyan N, Krobot KJ, Ulrich V. Cost of clinical events in health economic evaluations in Germany: a systematic review. Cost Eff Resour Alloc 2012;10(1):7
- Menzin J, Lines LM, Weiner DE, et al. A review of the costs and cost effectiveness of interventions in chronic kidney disease: implications for policy. Pharmacoeconomics 2011;29(10):839-61
- Trivedi HS, Pang MM, Campbell A, Saab P. Slowing the progression of chronic renal failure: economic benefits and patients’ perspectives. Am J Kidney Dis 2002;39(4):721-9
- Statistisches Bundesamt. Diagnosedaten der Patienten und Patientinnen in Krankenhäusern (einschl. Sterbe- und Stundenfälle). Wiesbaden; 2013a
- Statistisches Bundesamt. Sterbetafel 2009/2011. Wiesbaden; 2013b
- Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. Berlin: Quasi-Niere; 2008
- Heller G, Babitsch B, Günster C, Möckel M. Mortality following myocardial infarction in women and men: an analysis of insurance claims data from inpatient hospitalizations. Dtsch Arztebl Int 2008;105(15):279-85
- Günster C. Schlaganfallversorgung in Deutschland – Inzidenz, Wiederaufnahmen, Mortalität und Pflegerisiko im Spiegel von Routinedaten. In: Günster C, Klose J, Schmacke N, Versorgungsreport 2011. Schattauer; Stuttgart: 2011. pp. 147-63
- Statistisches Bundesamt. Krankheitskostenrechnung. Bonn; 2010